Taking insulin for type 2 diabetes could expose patients to greater risk of health complications

Examining the UK Clinical Practice Research Datalink (CPRD) - data that characterises about 10% of the UK population - a team of researchers from Cardiff University's School of Medicine looked at the risk of death for patients taking insulin compared with other treatments designed to lower blood glucose levels in people with type 2 diabetes.

The team's found people have greater risk of individual complications associated with diabetes such as heart attack, stroke, eye complications and when compared with patients treated with alternative glucose-lowering treatments.

" remains the most longstanding blood-glucose-lowering therapies for people with type 2 diabetes, with its use growing markedly in recent years," according to Professor Craig Currie from Cardiff University's School of Medicine, who led the study.

"However, with new diabetes therapies and treatments emerging there has been a new spotlight on treatments to ensure what the best and safest form of diabetes treatment is.

"By reviewing data from CPRD between 1999 and 2011 we've confirmed there are increased health risks for patients with type 2 diabetes who take insulin to manage their condition," he adds.

The study adds to previous findings which identified of insulin in this specific group of people.

Initial concerns were first raised regarding the use of insulin in type 2 diabetes from a population-based study in Canada, which reported a three-fold increase in mortality.

A similar study of people in UK primary care with type 2 diabetes treated with insulin also reported a 50% risk of increased mortality compared with another common .

Professor Currie adds: "Patients currently being treated with insulin should not, under any circumstances, stop taking their medications, and it is important to emphasise that this report related to only which typically starts in older people who are overweight.

"Each patient's individual circumstances are different and treatment decisions are managed by their clinician with all of their medical history fully considered.

"The vast majority of people who take insulin will experience no adverse effects and it remains a reliable and common form of treatment worldwide but this study shows that we need to investigate this matter urgently and the drug regulatory authorities should take interest in this issue.

"Anyone who is concerned should speak to their GP first before taking any action on managing their condition."

More information: Mortality and Other Important Diabetes-Related Outcomes With Insulin vs Other Antihyperglycemic Therapies in Type 2 Diabetes was published in The Journal of Clinical Endocrinology and Metabolism.

add to favorites email to friend print save as pdf

Related Stories

Treating diabetes

Jan 29, 2010

(PhysOrg.com) -- Uncontrolled high blood glucose levels in patients with diabetes (hyperglycaemia) is known to increase mortality, but new research led by the University shows that intensive treatment to control ...

Type 2 diabetes tablet promotes weight loss

Dec 06, 2012

(Medical Xpress)—A new drug for type 2 diabetes, involving research at Aston University is being launched as a once-daily tablet for adults with the condition.

Recommended for you

Diabetes and Thanksgiving can live in harmony

Nov 25, 2014

As you may know, November is National Diabetes Month. If you, a loved one, or a Thanksgiving guest have diabetes or prediabetes, this column is dedicated to you, as you may be wondering how to enjoy one of the most food-laden ...

Does a yogurt a day keep diabetes away?

Nov 24, 2014

A high intake of yogurt has been found to be associated with a lower risk of developing type 2 diabetes, according to research published in open access journal BMC Medicine. This highlights the importance of hav ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.